AIDS and Cancer Specimen Bank (ACSB)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to obtain clinical specimens from pathologists and physicians involved in the diagnosis and care of patients with AIDS and non-AIDS associated malignancies.
The National Cancer Institute has set up a Bank for tissues and biological fluids from HIVpositive and HIV-negative individuals in order to have specimens available for scientists studying malignancies associated with HIV disease.
| Condition |
|---|
|
Kaposi's Sarcoma AIDS Related Kaposi's Sarcoma Classical Non-Hodgkin's Lymphoma HEMATOPOIETIC SYSTEM Cancer AIDS |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | AIDS and Cancer Specimen Bank (ACSB) |
- Identify and improve access to tumor tissue, biological specimens, and associated clinical outcome data that could be utilized for research by the research community at-large on the pathogenesis of HIV and non-HIV associated malignancies. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Blood, urine, other bodily fluids (eg, pleural fluid), and tumor tissue obtained from patients.
| Enrollment: | 65 |
| Study Start Date: | June 1997 |
| Study Completion Date: | April 2011 |
| Primary Completion Date: | April 2011 (Final data collection date for primary outcome measure) |
The overall goal of the AIDS and Cancer Specimen Bank is to obtain clinical specimens from pathologists and physicians involved in the diagnosis and care of patients with AIDS and non- AIDS associated malignancies. These specimens will be banked and linked to a clinical data set so that experimental results obtained by analysis of specific specimens can be linked to relevant clinical data. Contents of the ACSB will be made available to researchers through an application to the National Cancer Institute. Strict patient confidentiality protection guidelines are in place for all specimens in the ACSB. The objective of this protocol is to obtain clinical specimens from potential participants in clinical trials conducted by the AIDS Malignancies Consortium, and from other patients with and without HIV infection, who have AIDS-Associated malignancies.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
The Source of specimens will include patients screened for participation on protocols conducted by the AIDS Malignancy Consortium, as well as other patients with HIV infection and cancer who are not eligible for participation in AMC trials, and patients without HIV who have malignancies associated with HIV or with immunosuppression.
Inclusion Criteria:
- Patient > 18 years of age
- Suspected or confirmed AIDS-Associated malignancy with or without HIV infection
- Will obtain fresh tissue and/or biological fluids
- Patient signed the correct version of the informed consent
Exclusion Criteria:
- N/A
Contacts and Locations| United States, New York | |
| Memorial Sloan-Kettering Cancer Center | |
| New York, New York, United States, 10065 | |
| Principal Investigator: | David Straus, MD | Memorial Sloan-Kettering Cancer Center |
More Information
Additional Information:
No publications provided
| Responsible Party: | David Straus, MD, Memorial Sloan-Kettering Cancer Center |
| ClinicalTrials.gov Identifier: | NCT00587912 History of Changes |
| Other Study ID Numbers: | 97-043 |
| Study First Received: | December 24, 2007 |
| Last Updated: | April 20, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Memorial Sloan-Kettering Cancer Center:
|
Kaposi's Sarcoma AIDS Related Kaposi's Sarcoma Classical Non-Hodgkin's Lymphoma |
HEMATOPOIETIC SYSTEM Cancer AIDS |
Additional relevant MeSH terms:
|
Acquired Immunodeficiency Syndrome HIV Infections Lymphoma Lymphoma, Non-Hodgkin Sarcoma, Kaposi AIDS-Related Opportunistic Infections Sarcoma Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Slow Virus Diseases |
Immunologic Deficiency Syndromes Immune System Diseases Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Herpesviridae Infections DNA Virus Infections Neoplasms, Connective and Soft Tissue Neoplasms, Vascular Tissue Opportunistic Infections Infection Parasitic Diseases |
ClinicalTrials.gov processed this record on February 21, 2013
